Dynorphin A(1-13) causes elevation of serum levels of prolactin through anopioid receptor mechanism in humans: Gender differences and implications for modulation of dopaminergic tone in the treatment of addictions
Mj. Kreek et al., Dynorphin A(1-13) causes elevation of serum levels of prolactin through anopioid receptor mechanism in humans: Gender differences and implications for modulation of dopaminergic tone in the treatment of addictions, J PHARM EXP, 288(1), 1999, pp. 260-269
Citations number
40
Categorie Soggetti
Pharmacology & Toxicology
Journal title
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Dynorphin peptides act preferentially at kappa- as well as mu- and delta-op
ioid receptors. This study was conducted to determine whether dynorphin pep
tides act to lower dopaminergic tone in the tuberoinfundibular system, resu
lting in elevated serum prolactin revels and, if so, whether such an effect
is mediated by the opioid receptors. Dose-related increases in serum prola
ctin levels were observed after dynorphin A(1-13) was administered i.v. in
doses of 120 and 500 mu g/kg to healthy human volunteers with no history of
drug or alcohol abuse. Studies were then conducted to determine whether th
is effect is opioid receptor mediated and, if so, whether at kappa- or mu t
ypes. Pretreatment with the opioid antagonist nalmefene (30 mg i.v.), which
has high affinity at both mu- and kappa-opioid receptors, caused a greater
attenuation in dynorphin A(1-13)-stimulated increases in serum prolactin l
evels than pretreatment with similarly high doses of naloxone, an antagonis
t with lower affinity for both mu- and kappa-opioid receptors. These result
s suggest dynorphin A(1-13) lowers tuberoinfundibular dopaminergic tone thr
ough action at kappa- and possibly mu-opioid receptors. Female subjects wer
e significantly more responsive to the prolactin effects of dynorphin than
were male subjects. Dynorphin gene expression, dynorphin peptides, and kapp
a-opioid receptor gene expression and binding have been shown to be altered
in response to cocaine administration. Also, both dynorphin peptides and s
ynthetic kappa-opioid agonists have been shown to lower dopamine levels in
the nucleus accumbens and to attenuate cocaine-induced surges in dopamine l
evels. Thus, a dynorphin-like compound capable of reaching critical mesolim
bic-mesocortical and nigrostriatal dopaminergic systems may be effective in
the management of cocaine addiction.